This approval of Xyrem by the FDA marks the first medicine approved to treat cataplexy or excessive daytime sleepiness in children and adolescents with narcolepsy ages seven and older
Efficacy and safety of Xyrem for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients with narcolepsy were established in a Phase 2/3 pivotal study
PR Newswire
DUBLIN, Oct. 29, 2018